Role of Oxidative Stress and Inflammation in Doxorubicin-Induced Cardiotoxicity: A Brief Account.
Roberta VitaleStefania MarzoccoAda PopoloPublished in: International journal of molecular sciences (2024)
Cardiotoxicity is the main side effect of several chemotherapeutic drugs. Doxorubicin (Doxo) is one of the most used anthracyclines in the treatment of many tumors, but the development of acute and chronic cardiotoxicity limits its clinical usefulness. Different studies focused only on the effects of long-term Doxo administration, but recent data show that cardiomyocyte damage is an early event induced by Doxo after a single administration that can be followed by progressive functional decline, leading to overt heart failure. The knowledge of molecular mechanisms involved in the early stage of Doxo-induced cardiotoxicity is of paramount importance to treating and/or preventing it. This review aims to illustrate several mechanisms thought to underlie Doxo-induced cardiotoxicity, such as oxidative and nitrosative stress, inflammation, and mitochondrial dysfunction. Moreover, here we report data from both in vitro and in vivo studies indicating new therapeutic strategies to prevent Doxo-induced cardiotoxicity.
Keyphrases
- oxidative stress
- diabetic rats
- high glucose
- heart failure
- early stage
- drug induced
- healthcare
- drug delivery
- multiple sclerosis
- machine learning
- electronic health record
- cancer therapy
- liver failure
- radiation therapy
- left ventricular
- induced apoptosis
- angiotensin ii
- artificial intelligence
- rectal cancer
- smoking cessation
- neoadjuvant chemotherapy
- aortic dissection